AzTrials
AzTrials

Alzheimer DiseasePhase 2NCT00895895

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

A Phase 2 study testing SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg in people with Alzheimer Disease, run by Pfizer at 96 sites in 13 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Alzheimer Disease
What is being tested?
SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
526 participants
Where
96 sitesin 13 countries
Study dates
May 2009to May 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of probable Alzheimer Disease according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Diseases and Related Disorders Association (NINCDS-ADRDA) criteria.
  • Mini-Mental State Examination (MMSE) score of 12 to 24 at screening
  • Rosen Modified Hachinski Ischemic score < or equal to 4 at screening.

Who cannot join

  • Relevant neurologic disease other than Alzheimer Disease that may affect cognition or ability to complete the study.
  • Current major depressive disorder or other current major psychiatric disorder.
  • History of clinically evident stroke or clinically important carotid or vertebrobasilar stenosis or plaque.
  • Use of prescription or nonprescription medications for cognitive enhancement (including memantine, ginkgo biloba, huperzine A, and cholinesterase inhibitors) within 3 months before the baseline visit.

Trial locations and contacts

96 sites in 13 countries.

96 sites in 13 countries

United States37 sites
  • Pfizer Investigational Site

    Allentown, Pennsylvania, 18104

  • Pfizer Investigational Site

    Atlanta, Georgia, 30308

  • Pfizer Investigational Site

    Atlantis, Florida, 33462

  • Pfizer Investigational Site

    Bennington, Vermont, 05201

  • Pfizer Investigational Site

    Brooksville, Florida, 34601

  • Pfizer Investigational Site

    Cedarhurst, New York, 11516

  • Pfizer Investigational Site

    Costa Mesa, California, 92626

  • Pfizer Investigational Site

    Denver, Colorado, 80218

  • Pfizer Investigational Site

    Denver, Colorado, 80239

  • Pfizer Investigational Site

    Elk Grove Village, Illinois, 60007

  • Pfizer Investigational Site

    Franklin, Tennessee, 37067

  • Pfizer Investigational Site

    Fresno, California, 93720

  • Pfizer Investigational Site

    Garden Grove, California, 92845

  • Pfizer Investigational Site

    Hallandale, Florida, 33009

  • Pfizer Investigational Site

    Long Beach, California, 90806

  • Pfizer Investigational Site

    Miami, Florida, 33180

  • Pfizer Investigational Site

    Middleton, Wisconsin, 53562

  • Pfizer Investigational Site

    Naples, Florida, 34102

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73103

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73116

  • Pfizer Investigational Site

    Oxnard, California, 93030

  • Pfizer Investigational Site

    Park Ridge, Illinois, 60068

  • Pfizer Investigational Site

    Phoenix, Arizona, 85004

  • Pfizer Investigational Site

    Phoenix, Arizona, 85050

  • Pfizer Investigational Site

    Plantation, Florida, 33317

  • Pfizer Investigational Site

    Portland, Oregon, 97210

  • Pfizer Investigational Site

    St Louis, Missouri, 63104

  • Pfizer Investigational Site

    St Louis, Missouri, 63110

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33702

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33709

  • Pfizer Investigational Site

    Staten Island, New York, 10312

  • Pfizer Investigational Site

    Sunrise, Florida, 33351

  • Pfizer Investigational Site

    Tampa, Florida, 33613

  • Pfizer Investigational Site

    Toledo, Ohio, 43623

  • Pfizer Investigational Site

    Tulsa, Oklahoma, 74104

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33407

Other trials in United States

Russia12 sites
  • Pfizer Investigational Site

    Kazan', 420101

  • Pfizer Investigational Site

    Moscow, 115522

  • Pfizer Investigational Site

    Moscow, 123182

  • Pfizer Investigational Site

    Nikolskoe Village, Gatchina District, Leningrad Region, 188357

  • Pfizer Investigational Site

    Novosibirsk, 630054

  • Pfizer Investigational Site

    Saint Petersburg, 190005

  • Pfizer Investigational Site

    Saint Petersburg, 192019

  • Pfizer Investigational Site

    Saint Petersburg, 194044

  • Pfizer Investigational Site

    Saint Petersburg, 197022

  • Pfizer Investigational Site

    Saint Petersburg, 198103

  • Pfizer Investigational Site

    Smolensk, 214018

  • Pfizer Investigational Site

    Yaroslavl, 150030

Other trials in Russia

Japan10 sites
  • Pfizer Investigational Site

    Chiba

  • Pfizer Investigational Site

    Fukuoka

  • Pfizer Investigational Site

    Hachiōji, Tokyo

  • Pfizer Investigational Site

    Hiroshima

  • Pfizer Investigational Site

    Kanagawa

  • Pfizer Investigational Site

    Kumamoto

  • Pfizer Investigational Site

    Kyoto

  • Pfizer Investigational Site

    Nagano

  • Pfizer Investigational Site

    Nagasaki

  • Pfizer Investigational Site

    Shizuoka

Other trials in Japan

Romania6 sites
  • Pfizer Investigational Site

    Bucharest, 010825

  • Pfizer Investigational Site

    Bucharest, 011241

  • Pfizer Investigational Site

    Bucharest, 041914

  • Pfizer Investigational Site

    Bucharest, 050098

  • Pfizer Investigational Site

    Craiova, Dolj, 200317

  • Pfizer Investigational Site

    Timișoara, Timiș County, 300736

Other trials in Romania

Chile5 sites
  • Pfizer Investigational Site

    Santiago, Chile, 7500922

  • Pfizer Investigational Site

    Santiago, Chile, 7530193

  • Pfizer Investigational Site

    Santiago, Chile, 7630000

  • Pfizer Investigational Site

    Santiago, Chile, 8330838

  • Pfizer Investigational Site

    Viña del Mar, Chile, 2520997

Other trials in Chile

Colombia5 sites
  • Pfizer Investigational Site

    Bogota, Cundinamarca

  • Pfizer Investigational Site

    Bucamaranga, Santander Department

  • Pfizer Investigational Site

    Cali, Valle del Cauca Department

  • Pfizer Investigational Site

    Pereira, Risaralda Department

  • Pfizer Investigational Site

    Valle Del Cauca

Other trials in Colombia

South Africa5 sites
  • Pfizer Investigational Site

    Bellville, Western Cape, 7530

  • Pfizer Investigational Site

    Bloemfontein, Free State, 9301

  • Pfizer Investigational Site

    Cape Town, 7530

  • Pfizer Investigational Site

    Johannesburg, Gauteng, 2196

  • Pfizer Investigational Site

    Pretoria, Gauteng, 0041

Other trials in South Africa

Argentina4 sites
  • Pfizer Investigational Site

    C.a.b.a., Buenos Aires, C1126AAB

  • Pfizer Investigational Site

    Caba, Buenos Aires, 1022

  • Pfizer Investigational Site

    Ciudad de Buenos Aires, 1022

  • Pfizer Investigational Site

    Ciudad de Buenos Aires, C1425BWO

Other trials in Argentina

Poland4 sites
  • Pfizer Investigational Site

    Krakow, Poland, 31-531

  • Pfizer Investigational Site

    Krakow, 31-531

  • Pfizer Investigational Site

    Poznan, Poland, 61-289

  • Pfizer Investigational Site

    Wroclaw, Poland, 50-088

Other trials in Poland

Hong Kong2 sites
  • Pfizer Investigational Site

    Hong Kong

  • Pfizer Investigational Site

    Shatin, N.T., Hong Kong SAR, China

Other trials in Hong Kong

Mexico2 sites
  • Pfizer Investigational Site

    Aguascalientes, 20127

  • Pfizer Investigational Site

    Saltillo, Coahuila, 25000

Other trials in Mexico

New Zealand2 sites
  • Pfizer Investigational Site

    Auckland, 0622

  • Pfizer Investigational Site

    Hamilton, 3240

Other trials in New Zealand

South Korea2 sites
  • Pfizer Investigational Site

    Seongnam-si, Gyeonggi-do, 463-707

  • Pfizer Investigational Site

    Seoul, 138-736

Other trials in South Korea

About this study

Official title: A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).

Read the detailed description

The study was stopped (date of termination was 13April2011) due to a 6 month interim analysis: all of the 3 SAM-531 dosage levels were declared futile. There were no safety concerns.

Being tested
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Medical subject headings
Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.

  • SAM-531 1.5 mgDrug

    Capsules SAM-531 1.5 mg, once a day during 52 weeks.

  • SAM-531 3.0 mgDrug

    Capsules SAM-531 3.0 mg, once a day during 52 weeks.

  • SAM-531 5.0 mgDrug

    Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.

  • DonepezilDrug

    Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.

Study groups in NCT00895895
Study groupRoleWhat they receive
1Placebo comparatorPlacebo
Receives: Drug: Placebo
2ExperimentalSAM-531 1.5 mg
Receives: Drug: SAM-531 1.5 mg
3ExperimentalSAM-531 3.0 mg
Receives: Drug: SAM-531 3.0 mg
4ExperimentalSAM-531 5.0 mg
Receives: Drug: SAM-531 5.0 mg
5Active comparatorDonepezil
Receives: Drug: Donepezil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24

    14-item scale to assess severity of cognitive impairment in Alzheimer's Disease. Items: word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, recall of test instructions, spoken language ability, word-finding difficulty, comprehension of spoken language, concentration/distractibility, number cancellation and executive maze. Rating scale ranged from 0 (not present) to 5 (severe). Total score was sum of individual scores (items 1-11) and ranged from 0 to 70 with higher scores indicating greater cognitive impairment.

    Measured: Baseline, Week 24

Secondary outcomes (19)
  1. Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24

    Caregiver interview-based instrument assessing 10 areas of activities of daily living (ADL) to measure participant's actual performance over the previous 2 weeks. Items included hygiene, dressing, continence, eating, meal preparation, telephoning, outings, finance/correspondence, medications and leisure/housework. Responses scored as 1 (yes) or 0 (no), response of "Not Applicable" was not scored. Total DAD score was sum of scores for 40 items, expressed as a percentage of the number of items answered yes or no. Total score ranged from 0 to 100, higher scores represented less disability in ADL.

    Measured: Baseline, Week 24

  2. Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24

    Caregiver interview-based rating scale assessed 10 behavioral, 2 neurovegetative disturbances occurring in dementia: delusions, hallucination, agitation/aggression, depression, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability, aberrant motor behavior, appetite/eating disorders and sleep/nightime behavior disorders. Each symptom score derived by symptom frequency (1 [occasionally] to 4 [very frequently] * symptom severity (1 [mild] to 3 [severe]) and ranged 0-12. Total score = sum of symptom scores; range 0-144, higher score indicating greater behavioral disturbances

    Measured: Baseline, Week 24

  3. Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24

    Caregiver and participant interview-based tool to rate the overall impression of participant's clinical change of the disease over time. Areas covered in the interview include: relevant history, observation/evaluation, mental/cognitive state, behavior and functioning. Change categorized into 1 of 7 categories: marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, marked worsening.

    Measured: Baseline, Week 24

  4. Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24

    CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total Errors=total number of incorrect boxes chosen plus adjustment for estimated possible errors on problems, attempts, and recalls not reached. Total score 0 to 106, lower scores=better performance.

    Measured: Baseline, Week 24

  5. Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24

    CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total score was the number of patterns presented at last stage successfully completed and ranged from 2 to 6, higher scores indicated better performance.

    Measured: Baseline, Week 24

  6. Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24

    CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total score was the number of correct choices made on the first attempt at each Stage. Total score ranged from 0 to 20, higher scores indicated better performance.

    Measured: Baseline, Week 24

  7. Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24

    CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 4 box assessments the maximum number of errors per trial was 20. Test ended with 20 errors in a trial. Less than 20 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 39. Lower scores: better performance.

    Measured: Baseline, Week 24

  8. Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24

    CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 6 box assessments the maximum number of errors per trial was 30. Test ended with 30 errors in a trial. Less than 30 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 59. Lower scores: better performance.

    Measured: Baseline, Week 24

  9. Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24

    CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 8 box assessments the maximum number of errors per trial was 40. Test ended with 40 errors in a trial. Less than 40 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 79. Lower scores: better performance.

    Measured: Baseline, Week 24

  10. Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24

    CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments, 2 trials for each assessment. Possible errors for each successful assessment: 4 box 0-38; 6 box 0-58; 8 box 0-78. Between Errors for N Boxes was the cumulative number of errors per each successful trial. Total scores ranged from 0 to 175. Lower scores indicated better performance.

    Measured: Baseline, Week 24

  11. Change From Baseline in CANTAB SWM Strategy at Week 24

    CANTAB-SWM assessed participant's ability to strategize. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments, 2 trials per assessment. Strategy score was the number of unique boxes the participant searched in the two 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 4 trial scores ranged from 4 to 28. Lower score indicated better performance.

    Measured: Baseline, Week 24

  12. Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24

    CANTAB-PRM assessed participant's visual pattern recognition memory in a 2-choice forced discrimination paradigm. Participants presented with a series of 12 visual patterns singly. In recognition phase, participants were required to choose between a pattern previously seen and a novel pattern. Patterns in the recognition phase appeared sequentially in reverse order on the screen. Assessment was repeated with 12 new patterns. Latency in correct responses ranged from 0 to infinity millisecond (msec), lower scores indicated better performance.

    Measured: Baseline, Week 24

  13. Change From Baseline in CANTAB PRM-Percentage Correct at Week 24

    CANTAB-PRM assessed participant's visual pattern recognition memory in a 2-choice forced discrimination paradigm. Participants presented with a series of 12 visual patterns singly. In recognition phase, participants were required to choose between a pattern previously seen and a novel pattern. Patterns in the recognition phase appeared sequentially in reverse order on the screen. Assessment was repeated with 12 new patterns. Correct response total expressed as a percentage, ranged from 0 to 100, higher scores indicated better performance.

    Measured: Baseline, Week 24

  14. Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24

    CANTAB-RTI assessed participant's reaction, movement time and vigilance during a 5-choice reaction time trial and to measure anticipatory/premature and perseverative responses. In the trial, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Accuracy was the total number of trials where participant responded correctly. Total ranged from 0 to 30, higher score indicated better performance.

    Measured: Baseline, Week 24

  15. Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24

    CANTAB-RTI assessed participant's reaction, movement time and vigilance during 5-choice reaction time trial and also measured anticipatory/premature responses. In the test, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Movement Time was the time from release of press pad to screen touch where the spot had been in trials the participant responded correctly. Possible score ranged from 100 to 5100 msec, lower score indicated better performance.

    Measured: Baseline, Week 24

  16. Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24

    CANTAB-RTI assessed participant's reaction, movement time and vigilance during 5-choice reaction time trial and also measured anticipatory/premature responses. In the test, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Reaction Time was the time from appearance of yellow spot on computer screen to time to release press pad in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.

    Measured: Baseline, Week 24

  17. Change From Baseline in CANTAB RTI Simple Movement Time at Week 24

    CANTAB-RTI assessed participant's reaction, movement time and vigilance during simple (1 choice) reaction time trial and also measured anticipatory/premature responses. In the test, 1 yellow spot appeared on a computer screen in 1 location, the participant responded by letting go of a press pad and touching the screen where the spot appeared. Simple Movement Time was the time from release of press pad to touch the screen where the spot had been in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.

    Measured: Baseline, Week 24

  18. Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24

    CANTAB-RTI assessed participant's reaction, movement time and vigilance during simple (1 choice) reaction time trial and also measured anticipatory/premature responses. In the test, 1 yellow spot appeared on a computer screen in 1 location, the participant responded by letting go of a press pad and touching the screen where the spot appeared. Simple Reaction Time was the time from appearance of yellow spot on computer screen to time to release press pad in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.

    Measured: Baseline, Week 24

  19. Percentage of Participants Who Were Responders at Week 24

    Responder defined as a participant who demonstrated an improvement of at least 3 points from baseline in the ADAS-Cog total score and no worsening in the DAD total score and in ADCS-CGIC. Participants were considered a responder at Week 24 if all 3 criteria were met.

    Measured: Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionMay 2011
  4. Study completionMay 2011

Why it stopped: See termination reason in detailed description.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
526 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00895895
Sponsor's protocol ID
3193A1-2005
Other IDs
B1961007
Status last verified
Dec 2012
First submitted
7 May 2009
Last updated
31 Jan 2013
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg in people with Alzheimer Disease, run by Pfizer at 96 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 31 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 96 sites in United States, Russia, Japan, Romania, Chile and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24 (time frame: Baseline, Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in